Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Tidiacic arginine** is an oral hepatoprotective small-molecule salt composed of L-arginine and tidiacic, also called thiazolidine-2,4-dicarboxylic acid, in a 1:1 ratio. It is marketed in France as **Tiadilon** 100 mg capsules for functional disorders presumed to be of hepatic origin. Tidiacic is described as a sulfur donor with antioxidant activity; however, no specific molecular target is established in the official product information. Historical controlled clinical studies evaluated arginine tidiacicate in chronic persistent hepatitis. ([agence-prd.ansm.sante.fr](https://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0371237.htm))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tidiacic arginine.